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Inhibition of endoproteolytic cleavage of glycoprotein B (gB; gpUL55) of human cytomegalovirus was achieved by treatment 
of infected fibroblasts with decanoyl peptidyl chloromethyl ketone (decRVKR-CMK), which inhibits the action of cellular 
subtilisin-like endoproteases with the amino acid recognition motif R X K/R R. Uncleaved gB precusor molecules of 160 
kDa that were accumulated were endogiycosidase H resistant, suggesting that correct cellular transport occurred in the 
presence of the drug. The inhibitor also prevented endoproteolytic gB processing in CV-1 cells infected with a recombinant 
vaccinia virus-gB construct (WgB). Evidence for direct involvement of the ubiquitous subtilisin-like endoprotease furin in 
gB cleavage was obtained from the observation that coinfection of CV-1 cells with VVgB and a recombinant vaccinia-human 
furin construct reestablished endoproteolytic activity which was normally absent late after infection with WgB alone. 
© 1995 Academic Press, Inc. 
Glycoprotein B, gB (gpUL55), of human cytomegalovi- 
rus (HCMV) represents the abundant and immunodomi- 
nant component of the viral envelope (1). Glycoprotein B 
homologs are highly conserved within the herpesvirus 
family (1), an observation that reflects their essential bio- 
logical function, most likely in membrane fusion pro- 
cesses during viral entry and cell-to-cell spread (2). Inter- 
estingly, maturation of most of the herpesvirus gB pro- 
teins, e.g., that of HCMV, includes post-translational 
processing of the glycosylated precursor by proteolytic 
cleavage into two products that remain linked by disul- 
fide-bonds (3), whereas in some species, e.g., in the case 
of herpes simplex viruses gB (4), there is no cleavage 
step involved in processing. The biological significance 
of herpesvirus gB cleavage does apparently not consist 
in endoproteolytic activation of a fusogenic domain of 
the molecule, as demonstrated for the membrane glyco- 
proteins of, e.g., orthomyxoviruses (5; see below). 
Endoproteolytic cleavage of a 160-kDa precursor of 
HCMV gB yields an amino-terminal product of about 100 
kDa and a carboxy-terminal product of about 58 kDa (6; 
Fig. 1A, lanes pulse and chase, minus inhibitor). Regard- 
ing the enzyme involved in cleavage, the conclusion was 
drawn from the consistent observation of its correct en- 
doproteolytic processing after expression of the solitary 
gB gene in a variety of cells, that gB cleavage is executed 
by an ubiquituous cellular endoprotease. The deduced 
amino acid sequence at the cleavage site of HCMV gB, 
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R T K/R R$ (7), represents the recognition motif of the 
subtilisin-like serine endoprotease furin recently discov- 
ered in animal cells (8). 
In order to characterize the enzyme mediating cleav- 
age of HCMV gB, two sets of experiments were per- 
formed. In the first set, parallel cultures of human fibro- 
blasts (1.5 x 106 cells each) were infected with the 
AD169 strain of HCMV with a multiplicity of infection 
(m.o.i.) of approximately 3. At 72 hr postinfection (p.i.) the 
cultures were pulse labeled for 1 hr with [35S]methionine 
(50 #Ci/ml), thoroughly washed with PBS, and subse- 
quently chased for 3 hr in the presence of excess unla- 
beled methionine and various concentrations of the in- 
hibitor decanoyl-peptidyl (R V K R)-chloro-methyl ketone 
(decRVKR-CMK; 9), which contains the consensus se- 
quence for recognition by furin. To test for cytotoxicity 
and reversibility of a possible inhibitory effect, an infected 
culture was labeled in the presence of and chased with- 
out inhibitor. After pulse or pulse and chase, cell extracts 
were prepared and immunoprecipitated with gB-specific 
monoclonal antibody (mAb 27-156; 7) prior to electro- 
phorectic separation of the precipitates and fluorography 
as described previously (10). Under these conditions, in- 
hibitor concentrations as little as 5 #M efficiently pre- 
vented appearance of the cleavage products (Fig. 1A, 
lanes chase, plus inhibitor), at the same time a slow 
migrating gB-specific product of about 160 kDa accumu- 
lated which most likely represented a normally short- 
lived processing intermediate carrying complex carbohy- 
drate side chains (6). This type of modification is thought 
to occur in the trans-Golgi-network prior to endoproteo- 
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FiG. 1. Inhibition of endoproteolytic cleavage of HCMV gB in decRVKR-CMK-treated infected human fibroblasts and glycosidase sensitivity of gB 
from inhibitor-treated cells. (A) Parallel cultures (1.5 x 106 cells each) of HCMV (strain AD169)-infected fibroblasts were pulse labeled at 72 hr p,i. 
with [35S]methionine (50 #Ci/ml) for 1 hr prior to a chase interval of 3 hr. The inhibitor was either absent (Inhib. - )  during pulse and chase (lanes 
pulse and chase), present (25 #M) only during the pulse (Inhib. o, lane Recovery), or present (Inhib. ÷) at various concentrations only during the 
chase ~n~s~cl~a~i~9~'/~r~hC.d~,2~:;d/~/)d~Ol:AflEIr-lt~8~ ~a~d~r~e~se and chase cell extracts were subjected to immunoprecipitation with mab 
untreated cells (Pulse and Chase w/o) and inhibitor-treated cells (Chase 25 #M) were digested with endo H or PNGase F (lanes endo H or PNGase 
F + or -)  prior to analysis by SDS-PAGE and fluorography. The relative migration of the marker proteins myosin (200 kDa), phosphorylase b (97 
kDa), bovine serum albumin (69 kDa), and aldolase (40 kDa) is indicated on the left of (A) and (B), that of gB precursor (P), aminoterminal (N), and 
carboxyterminal (C) cleavage products is indicated on the right of (A). Coprecipitation of a polypeptide of about 65 kDa was frequently observed 
independently of inhibitor use (see text). 
lytic cleavage in the same cellular compartment (6). 
When decRVKR-CMK (25 #M) was present during the 
pulse interval, incorporation of methionine was not pre- 
vented showing that the inhibitor was not toxic. Also, the 
inhibitory action of the drug was not reversed during the 
drug-free chase period because there was no recogni- 
tion of gB cleavage products, but again accumulation of 
the processing intermediate occurred under these condi- 
tions (Fig. 1A, lane recovery). In precipitates from un- 
treated as well as inhibitor-treated chase samples (Fig. 
1A, particularly pronounced in chase 25 #M), a polypep- 
tide of about 65 kDa was frequently seen which is known 
to be coprecipitated from infected cells by the gB-specific 
monoclonal antibody used here (11). 
To directly address the question of endo H-resistance 
0fthe 160-kDa gB processing intermediate, immunopre- 
cipitates of chase samples of drug-treated cells were 
digested with endoH or endoglYCosidase F (PNGase F) 
and analyzed (10; Fig. 1B). Pulse and chase samples 
from untreated cells served as controls. This comparative 
analysis revealed sensitivity for either glycosidase of gB 
precursor and partial endo H resistance of cleavage 
products from untreated cells (Fig. 1 B, panels pulse and 
chase w/o) and clearly endo H resistance of the 160 
kDa gB intermediate (Fig. 1 B, panel chase 25 #M). This 
observation suggested that he uncleaved gB molecule 
was correctly transported in inhibitor-treated cells. It is 
noteworthy in this context that virus titers determined 
from the chase media showed that about equal amounts 
of viral progeny were released from untreated and drug- 
treated cultures during the chase interval (about 2 x 104 
infectious units/ml), indicating again absence of interfer- 
ence with cellular transport and of cytotoxicity. Previously 
it was demonstrated for palmitoyl-peptidyI-CMK-treated 
(palFAKR-CMK) infected cells that uncleaved gB precur- 
sor may become associated with extracellular virions 
(11). This observation was extended for decRVKR-OMK- 
treated infected cells used here by immunoprecipitation 
with mAb 27-156 of uncleaved gB from extracellular viri- 
ons (data not shown). Regarding our previous observa- 
tion that paIFAKR-CMK, which does not contain the com- 
plete recognition motif for cellular furin (11), also inhibited 
HCMV gB cleavage may have been due to the higher 
near-toxic concentrations needed as compared to those 
used here with the new inhibitor decRVKR which was 
formerly not available. 
In the second set of experiments recombinant HCMV- 
gB in a vaccinia virus vector was used (12). Radiolabeling 
with [35S]methionine (50 #Ci/ml at 4.5-5.5 hr p.i. prior to 
2 hr chase) early after infection of cultures of CV-1 cells 
(m.o.i. of approximately 10; 1 X 106 cells each) with this 
construct and subsequent analysis of the immunoprecip- 
itates revealed correct endoproteolytic processing of the 
gB molecule (Fig. 2A, lane WgB w/o). Presence of 
decRVKR-CMK in the medium efficiently prevented endo- 
proteolytic cleavage of the recombinant gB and again 
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FI6.2. (A) Inhibition of endoproteolytic cleavage of recombinant vac- 
cinia virus gB by decRVKR-CMK. Parallel cultures of CV-1 cells (I x 
106 cells each) were infected with a recombinant vaccinia virus gB 
construct at a m.o.i, of 10, without (WgB w/o) or in the presence of 
decRVKR-CMK (WgB 50 #M) and pulse labeled with [35S]methionine. 
(50 #Ci/mt) from 4.5-5.5 hr p.i. prior to immunoprecipitation of cell 
extracts with mab 27-156 and analysis of the precipitates by SDS- 
PAGE and fluorography. (B) Reestablishment of endoproteolytic a tivity 
late after WgB infection by coexpression with Whfur. Parallel cultures 
of CV-1 cells were infected either with WgB alone (WgB) as under (A) 
or coinfected at equal m.o.i, with Whfur (WgB x Whfur) and pulse 
labeled with [3SS]methionine (50 #Ci/ml) from 17-18 hr p.i. prior to 
immunoprecipitation with mab 27-156 (anti gB+) or with polyclonal 
antifurin (anti fur.) and analysis of the precipitates by SDS-PAGE and 
fluorography. The relative migration of the identical marker p oteins 
listed in the legend.of Fig. 1 is indicated on the left, that of gB precursor 
(P), carboxyterminal clevage product (C), and furin (Fur) is indicated on 
the right. 
led to accumulation of the above-mentioned 160-kDa gB 
intermediate (Fig. 2A, lane WgB 50 tiM). In an additional 
experimental approach advantage was taken of the ob- 
servation that late after infection with vaccinia virus (18 
hr p.i., 1 hr pulse prior to 2 hr chase) endogenous cellular 
endoprotease activity is apparently depleted (•3); by 
coinfection with recombinant vaccinia virus carrying the 
human furin gene (Whfur), endoproteolytic activity may 
be reestablished (9, 13). Therefore, CV-1 cell cultures 
were coinfected with both vaccinia virus gB (WgB) and 
Whfur and radiolabeled as described above with [3~S]- 
methionine for 1 hr at 18 hr p.i. prior to immunuprecipita- 
tion of gB; cells infected with WgB alone served as a 
control. Under these conditions precipitates obtained 
with mAb 27-156 from WgB-infected cells contained 
uncleaved gB precursor as well as 160-kDa intermediate 
(Fig. 2B, lane WgB, + anti gB), and those from coinfected 
cells contained in addition to uncleaved gB precursor 
cleavage products of gB (Fig. 2B, lane WgB X Whfur, 
+ anti gB). Immunoprecipitation with antifurin verified 
for the coinfected cultures correct expression also of 
recombinant furin (Fig. 2B, lane WgB x Whfur, 4- anti- 
fur), which obviously reestablished the endoproteolytic 
activity in this system. 
The experiments presented indicate that the cellular 
endoprotease furin is a prime candidate for proteolytic 
cleavage during maturational processing of HCMV gB in 
infected cells. This conclusion is based on the following 
observations, First, the inhibitor decRVKR-CMK with the 
furin recognition motif R V K/R R prevented cleavage of 
HCMV gB in different systems. In addition to the experi- 
mental setups described here, inhibition of gB cleavage 
by the drug-was also observed in HCMV-infected astro- 
cytoma cells and in transfected astrocytoma cell lines 
stably expressing gB (10; data not shown). Interestingly, 
in the presence of the inhibitor consistent accumulation 
was noticed of a normally short-lived, endo H-resistant 
gB intermediate which is most likely the immediate sub- 
strate of the end0Protease. Second, coexpression experi- 
ments showed that recombinant human furin promoted 
directly endoproteolytic leavage of recombinant HCMV 
gB in the absence of endogenous cellular proteolytic 
activity. 
Recently, a cell line, LoVo, was described lacking a 
functional furin gene (14). Interestingly, two viral mem- 
brane glyoproteins, gp 160 of human immunodeficiuency 
virus (HIV) and the fusion glycoprotein of Newcastle dis- 
ease virus which were both thought to be proteolytically 
cleaved by furin, are differently processed in LoVo cells 
(15). Unexpectedly, HIV gp160 was found to be correctly 
processed in spite of the absence of functional furin. 
This observation indicated that endoproteases other than 
furin may function at the R x K/R R-recognition motif. It 
is noteworthy in this context that two other ubiquitous 
endoproteases, PACE 4 and PC6, that resemble furin in 
their cleavage specificities (16, I7) have been recently 
identified. Thus, it cannot be excluded that furin may not 
be the only cleavage enzyme of HCMV gB. 
Regarding the biological significance of the herpesvi- 
rus gB cleavage step, it has been demonstrated that gB 
of bovine herpes virus 1 (BHV-1), which was rendered 
uncleavable by mutagenesis, could functionally substi- 
tute for the cleavable counterparts of BHV-1 as well as 
of pseudorabies virus (18). Cleavage of the gB molecule 
appears thus not to be essential for its function under 
the in vitro test conditions. However, it may well be that 
the conformational alteration resulting from cleavage at 
the conserved recognition site may be necessary, e.g., 
for improvement of viral infectious potential and propaga- 
tion in certain cell types in vivo. This aspect should be 
amenable to experimental examination. With respect to 
the structure of herpesvirus gB cleavage products, there 
is no obvious fusogenic peptide which is proteolytically 
activated like in the case of influenza virus hemagglutinin 
or human immunodeficiency virus glycoprotein 160 kDa 
(for review see 19). An intramolecular hydrophobic do- 
main neighboring the actual membrane anchor domain 
with striking sequence similarity to fusogenic peptides 
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has recently been recognized for herpesvirus gB (20). So 
far the structural conception for the fusogenic activity 
attributed to herpesvirus gB-type molecules is still largely 
enigmatic. Precise structural analysis of the gB molecule 
is needed to eventually elucidate its functional structure. 
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